A comparison between the MoCA and the MMSE visuoexecutive sub-tests in detecting abnormalities in TIA/stroke patients

Lauren, M.; Sposato, Luciano A.; Rothwell, Peter M.; Hachinski, Vladimir; Pendlebury, Sarah T.

doi:10.1177/1747493016632238

Cited by 29 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMSE and MoCA are the two most common scales used to test cognitive impairment in various neurological dysfunctions, such as stroke and dementia [25,26]. MMSE was developed to assess cognitive dysfunction in Alzheimer’s disease, which is marked by difficulties in memory progress and language, and the scale is less frequently coupled with executive function, word-finding, and visual spatial ability deficits in early diagnosis [27].…”

Section: Discussionmentioning

confidence: 99%

Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case–control study

et al. 2017

View full text Add to dashboard Cite

The present study was designed to explore the correlation between serum S100β levels and cognitive dysfunction in patients with cerebral small vessel disease (SVD). A total of 172 SVD patients participated in the study, and they were assigned to patients with no cognitive impairment (NCI group) and those with vascular cognitive impairment no dementia (VCIND group). In total, 105 people were recruited into the normal control group. Serum S100β protein level was detected by ELISA. A receiver operating characteristic (ROC) curve was employed for the predictive value of serum S100β in diagnosing SVD with cognitive dysfunction. Pearson correlation analysis was used to examine the association of S100β level with mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA) and the association of S100β levels with hypertension. Logistic regression analysis was used to analyze risk factors of SVD. The serum S100β levels in the VCIND group were higher than those in the NCI and normal control groups. Logistic regression analysis revealed that a high serum S100β protein level, hypertension, and high low density lipoprotein-cholesterol (LDL-C) level were the independent risk factors for SVD. In addition, hypertension patients showed higher S100β levels than those with normal blood pressure and the normal control group, and there was a positive correlation between S100β level and blood pressure. The concentration of serum S100β level was related to impairment of cognition function of VCIND patients, therefore, early detection of serum S100β was of great value for diagnosis of SVD.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case–control study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The MoCA has good psychometric properties and is a valid screening tool to detect post-stroke cognitive impairment [13]. Although a recent study [14] questioned the accuracy of the MoCA to assess attention and executive function by stroke lateralization, the majority of studies have shown the MoCA to be superior compared to other screening measures such as the MMSE [11, 15, 16]. While primarily considered a screening tool, the MoCA has been used as a cognitive outcome measure in longitudinal studies where lengthy neuropsychological testing is not often feasible.…”

Section: Assessmentmentioning

confidence: 99%

Determinants, Prevalence, and Trajectory of Long-Term Post-Stroke Cognitive Impairment: Results from a 4-Year Follow-Up of the ARCOS-IV Study

et al. 2017

View full text Add to dashboard Cite

Background: The long-term (>12 months) prevalence, predictors, and trajectory of post-stroke cognitive deficits are not well established, especially at a community level. This study investigated the longitudinal course and prevalence of cognitive impairment in an incidence cohort, identifying factors associated with declining cognition. Methods: Two hundred fifty-seven participants (mean age = 67.93 ± 13.59) of first-ever stroke survivors, completed cognitive assessments within 2 weeks post stroke, and/or 1, 6, 12, and 48-month. Multivariate linear and logistic models were used to identify baseline predictors (reported as OR with 95% CI) and trajectory of cognitive impairment. Results: Cognitive functioning significantly declined by 2.8 points by 4 years post stroke. Eighty-four percent of stroke survivors had cognitive impairment indicative of post-stroke dementia (mean Montreal cognitive assessment = 20 ± 4.7) at 4-year. There were significant associations between progressive cognitive decline and the following factors: male gender (OR 2.9, 95% CI 1.6–5.9, p = 0.0171), coronary artery disease (OR 2.96, 95% CI 1.35–6.49, p = 0.0070), arrhythmia (OR 2.21, 95% CI 1.07–4.57, p = 0.0317), not in a relationship (OR 2.8, 95% CI 1.4–5.50, p < 0.0001), and not employed (OR 4.9, 95% CI 1.9–12.1, p < 0.0001). Conclusions: Cognitive deficits remain highly prevalent at 4-year post stroke. Early identification of those at higher risk of declining cognition is vital to target rehabilitation interventions at the acute stage and improve overall outcomes.

show abstract

“…Our findings also highlight the differences between two extensively used screening tests of global cognition, that is, MMSE and 11,17,18,20,28 The studies reported that the relative performance of MMSE and MoCA depends on the type/degree of cognitive impairment aimed to be detected. 11,12,18,28 In our study, the stroke survivors had a higher educational level than the controls, possibly because of slightly different geographical uptake areas.…”

Section: Discussionmentioning

confidence: 65%

“…When adjusting for this, the odds of having severe cognitive impairment defined as MMSE<23 were 2.5 times higher among the stroke survivors as compared to the controls. 20 We also noted that the MMSE word recall subtest scoring of the controls was surprisingly low (Table S2). 8,9 We further found that 10-year stroke survivors performed worse on the MMSE visuoconstruction subtest compared to controls, suggesting a higher prevalence of visuoexecutive deficits.…”

Section: Discussionmentioning

confidence: 88%

“…[13][14][15] The Montreal Cognitive Assessment (MoCA) was more recently developed to also detect MCI. [17][18][19][20] As long-term PSCI (≥10 years after stroke) is scarcely studied, it is unclear whether the reported differences in the relative performance of MMSE and MoCA also hold true for such long-term post-stroke assessment. [17][18][19][20] As long-term PSCI (≥10 years after stroke) is scarcely studied, it is unclear whether the reported differences in the relative performance of MMSE and MoCA also hold true for such long-term post-stroke assessment.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cognitive function in stroke survivors: A 10-year follow-up study

et al. 2016

View full text Add to dashboard Cite

show abstract

A comparison between the MoCA and the MMSE visuoexecutive sub-tests in detecting abnormalities in TIA/stroke patients

Cited by 29 publications

References 16 publications

Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case–control study

Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case–control study

Determinants, Prevalence, and Trajectory of Long-Term Post-Stroke Cognitive Impairment: Results from a 4-Year Follow-Up of the ARCOS-IV Study

Cognitive function in stroke survivors: A 10-year follow-up study

Contact Info

Product

Resources

About